Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -6.56% is 196% below its 5-year average of 6.83%, near the low end of its 5-year range (-6.56%–14.42%).
186.15% below its 12-month average of 7.62%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
-6.56%
RETURN ON ASSETS (ROA) AVG TTM
7.62%
RETURN ON ASSETS (ROA) AVG 3Y
7.90%
RETURN ON ASSETS (ROA) AVG 5Y
6.83%
RETURN ON ASSETS (ROA) AVG 10Y
11.23%
RETURN ON ASSETS (ROA) AVG 15Y
11.11%
RETURN ON ASSETS (ROA) AVG 20Y
16.53%
CURRENT VS TTM AVG
-186.15%
CURRENT VS 3Y AVG
-182.99%
CURRENT VS 5Y AVG
-196.09%
CURRENT VS 10Y AVG
-158.40%
CURRENT VS 15Y AVG
-159.02%
CURRENT VS 20Y AVG
-139.70%
SECTOR MEDIAN · HEALTHCARE
5.14%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
-227.63%
vs the sector median at left
Gilead Sciences, Inc.
Market Cap
$182.25B
Return on Assets (ROA)
-6.56%
TTM Avg
7.62%
3Y Avg
7.90%
5Y Avg
6.83%
Market Cap
$182.82B
Return on Assets (ROA)
4.97%
TTM Avg
11.99%
3Y Avg
10.28%
5Y Avg
9.45%
Market Cap
$200.83B
Return on Assets (ROA)
19.90%
TTM Avg
20.27%
3Y Avg
22.54%
5Y Avg
48.60%
Market Cap
$158.53B
Return on Assets (ROA)
2.16%
TTM Avg
3.75%
3Y Avg
6.08%
5Y Avg
7.08%
Market Cap
$213.09B
Return on Assets (ROA)
9.14%
TTM Avg
6.48%
3Y Avg
7.48%
5Y Avg
8.52%
Market Cap
$144.95B
Return on Assets (ROA)
4.33%
TTM Avg
4.68%
3Y Avg
5.89%
5Y Avg
6.01%
Market Cap
$224.62B
Return on Assets (ROA)
6.17%
TTM Avg
6.31%
3Y Avg
6.46%
5Y Avg
7.20%
Market Cap
$134.35B
Return on Assets (ROA)
16.06%
TTM Avg
6.37%
3Y Avg
11.74%
5Y Avg
14.58%
Market Cap
$132.30B
Return on Assets (ROA)
10.59%
TTM Avg
-0.92%
3Y Avg
3.28%
5Y Avg
1.99%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. (GILD) | $182.25B | -6.56% | 7.62% | 7.90% | 6.83% |
| Abbott Laboratories (ABT)vs › | $182.82B | 4.97% | 11.99% | 10.28% | 9.45% |
| Novo Nordisk A/S (NVO)vs › | $200.83B | 19.90% | 20.27% | 22.54% | 48.60% |
| Pfizer Inc. (PFE)vs › | $158.53B | 2.16% | 3.75% | 6.08% | 7.08% |
| Amgen Inc. (AMGN)vs › | $213.09B | 9.14% | 6.48% | 7.48% | 8.52% |
| Danaher Corporation (DHR)vs › | $144.95B | 4.33% | 4.68% | 5.89% | 6.01% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.62B | 6.17% | 6.31% | 6.46% | 7.20% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $134.35B | 16.06% | 6.37% | 11.74% | 14.58% |
| Bristol-Myers Squibb Company (BMY)vs › | $132.30B | 10.59% | -0.92% | 3.28% | 1.99% |
| Intuitive Surgical, Inc. (ISRG)vs › | $123.94B | 15.04% | 13.09% | 12.00% | 11.68% |
ROA
-6.6%
ROE
-27.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 14.42% |
| 2024-12-31 | 0.81% |
| 2023-12-31 | 9.12% |
| 2022-12-31 | 7.27% |
| 2021-12-31 | 9.16% |
| 2020-12-31 | 0.18% |
| 2019-12-31 | 8.74% |
| 2018-12-31 | 8.57% |
| 2017-12-31 | 6.58% |
| 2016-12-31 | 23.70% |
| 2015-12-31 | 35.01% |
| 2014-12-31 | 34.91% |
| 2013-12-31 | 13.62% |
| 2012-12-31 | 12.20% |
| 2011-12-31 | 16.20% |
| 2010-12-31 | 25.03% |
| 2009-12-31 | 27.18% |
| 2008-12-31 | 28.53% |
| 2007-12-31 | 27.68% |
| 2006-12-31 | -29.12% |
| 2005-12-31 | 21.61% |
| 2004-12-31 | 20.84% |
| 2003-12-31 | -4.63% |
| 2002-12-31 | 5.60% |
| 2001-12-31 | 6.58% |
| 2000-12-31 | -8.37% |
| 1999-12-31 | -15.22% |
| 1998-12-31 | -9.18% |
| 1997-12-31 | -20.70% |
| 1996-12-31 | -6.98% |
